We report a case of a 33 year old male with chronic graft-versus-host-disease (cGvHD) of the skin and severe immune-mediated thrombocytopenia refractory to any treatment modality. The patient had undergone bone marrow transplantation for CML in first chronic phase 2 years ago. He developed cGvHD of the skin and remained steroid dependent. At the onset of the autoimmune thrombocytopenia he received prednisolone 20 mg/day, mycophenolate mofetil 2g/day and cyclosporine A in therapeutic levels, all as treatment for cGvHD. Autoantibodies against platelet antigens could be detected with the MAIPA test. Despite treatment with steroids, gamma globulin and splenectomy, only short-term of platelet increases could be achieved. Finally, treatment with rituximab, an anti-CD20 chimeric monoclonal antibody, was started at a dose of 375 mg/m 2 weekly for 4 weeks. The infusions were performed on an outpatient basis and were tolerated well. The therapy resulted in a depletion of B cells in the peripheral blood and decreased levels of platelet autoantibodies. The increased platelet count (up to 279 x 10e9/l) persisted over 3 months despite tapering of immunosupppressive therapy. Single cases of successful treatment with rituximab for immune mediated thrombocytopenia associated with cGvHD have been reported in the last years. The autoimmune mediated thrombocytopenia in chronic graft-versus-host Disease seems to be due to a cellular immune dysfunction, resulting in the production of autoantibodies. The pathological B cell clones can be efficiently eliminated by anti-CD20 antibody. The use of rituximab may be warranted in most autoimmune syndromes associated with cGvHD.
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Between November 1978 and May 1998, 311 patients underwent allogeneic stem cell transplantation (SCT) from syngenic (n=8) or allogeneic siblings (n=243) or unrelated donors (n=60) because of acute leukemia (AL, n=133), chronic myeloid leukemia (CML, n=98), multiple myeloma (MM, n=9), myelodysplastic syndrom (MDS, n=12), non-Hodgkins lymphoma (NHL, n=29), severe aplastic anemia (SAA, n=24), and others (n=6). One hundred thirty-six pts died during the first year after SCT due to relapse (n=57) or transplant related complications (n=79), 20 pts died during the second year after SCT, 14 due to relapse. We studied the long-term outcome of the remaining 155 pts (m/f=86/69) who were alive and in complete remission two years after syngenic (n=6) or allogeneic SCT from siblings (n=125) or unrelated donors (n=24). Median age at transplant was 35 (range, 17-57) yrs. Diagnosis consisted of AL (n=52), CML (n=56), MM (n=5), MDS (n=7), NHL (n=15), SAA (n=19), testicular cancer (n=1). One hundred forty-six donors had been HLA-identical whereas 7 had an 1-antigen mismatch and 2 had 2-antigen mismatches. Eighty-nine (57%) pts experienced acute graft versus host disease (GvHD) and 81 (52%) chronic GvHD. Nineteen (12%) pts relapsed 25-142 months (median 48) after SCT. Fourteen (9%) pts died of relapse whereas 1 pt is in complete remission after second SCT and 4 are alive with disease. Six pts were lost for follow-up 6 to 13 years after SCT. After a median follow-up of 38 (range, 1-188) months from the 2-year mark, 135 (87%) are alive including 131 disease free. Six (4%) pts died 36 to 192 months after SCT of chronic GvHD (n=4), hepatic failure due to hepatits B and C (n=1) and squamous cell cancer (n=1). The 15-year probability of survival, relapse and toxic death (from the 2-year mark) are 78, 19 and 7%. Ten/149 (7%) pts have ongoing chronic GvHD and are under immunosuppression but 124 (83%) have a Karnofsky index Ͼ90%. Thus, pts surviving disease-free more than 2 years after allogeneic SCT have an excellent long-term prognosis. (1) have reported that sucralfate instilled intravesiculary before and after formaldehyde infusion protects the rabbit bladder urothelium against chemically induced cystitis. We here report our seven first patients with HC after allogeneic HSCT who underwent treatment with intravesicular instillation of sucralfate. All patients received conditioning including cyclophosophamide and GVHD prophylaxis with cyclosporin A and methotrexate. Sucralfate, 2g in 10 ml of sterile Sodium Chloride, was instilled daily by an indwelling urinary catheter as soon as macroscopic hematuria appeared and until signs of HC had resolved. In conclusion, four patients responded to sucralfate instillation, three patients responded but HC relapsed after discontinuation of sucralfate and one patient did not respond. Two patients were not evaluable, since they deceased with ongoing HC. The results of this study indicate that intravesicular sucralfate may have an effect on HC, but further investigations are needed. Allogeneic stem cell transplantation (SCT) has a high curative potential in various hematologic diseases. In about 20% of donorrecipient pairs ABO incompatibility exsists. Nevertheless in a minority of minor or bidirectional ABO-incompatiblity delayed immune hemolysis can occur due to donor derived hemagglutinins directed against recipient RBC antigenes. In general this hemolysis is moderate but 10-15% of patients develop severe complications. We here report three cases of severe hemolysis occuring after minor ABO-incompatible SCT. Patients characteristics are given in table below. In all 3 patients hemoglobin and haptoglobin levels decreased below 7.3 g/dl and 30 mg/dl, respectively and levels of serum bilirubin (3.4-50.6 mg/dl), LDH( 431-2430 U/l) and in pt 1 and 3 creatinine (1.68 and 1.45 mg/100ml) increased at the time of apperence of donor hemagglutinins. Because of increase of renal parameters and deterioration in the patients condition we decided to perform red blood cell exchange (RE). Washed RBCs of blood group 0 were used as substituat. In addition in patient 1 and 3 plasmaexchange (TPE) was performed because of high levels of serum bilirubin (50.6 mg/dl) in pt 1 and suspected thrombotic thrombocytopenic purpura with high LDH levels (2430 U/L) and increasing fragmentocytes in pt 3, respectively. In pt 1, two RE and 2 TPE had to be performed whereas pt 2 required only one RE. Both are in excellent condition 52 and 2.5 months after SCT. Patient 3 required 2 RE and 2 TPE but died on day +30 due to multi organ failure. Because of the reported dismail prognosis of patients developing severe hemolysis after minor ABO-incompatible SCT hemagglutinin titer should be monitored in early post-transplant period until engraftment. We recommend RBC exchange as an effective treatment of severe hemolysis wich improves the outcome in these patients.
